S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
The single greatest medical breakthrough of all time? (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
The single greatest medical breakthrough of all time? (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
The single greatest medical breakthrough of all time? (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
This Little Known Automaker May Save Your Life and Your Portfolio
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
The single greatest medical breakthrough of all time? (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
The single greatest medical breakthrough of all time? (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
The single greatest medical breakthrough of all time? (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
This Little Known Automaker May Save Your Life and Your Portfolio
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
The single greatest medical breakthrough of all time? (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
The single greatest medical breakthrough of all time? (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
The single greatest medical breakthrough of all time? (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
This Little Known Automaker May Save Your Life and Your Portfolio
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
The single greatest medical breakthrough of all time? (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
The single greatest medical breakthrough of all time? (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
Stock market today: Global shares mostly fall over China worries
The single greatest medical breakthrough of all time? (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
This Little Known Automaker May Save Your Life and Your Portfolio

Mineralys Therapeutics (MLYS) Stock Forecast, Price & News

$9.85
-0.25 (-2.48%)
(As of 09/27/2023 ET)
Compare
Today's Range
$9.70
$10.26
50-Day Range
$9.85
$15.11
52-Week Range
$9.70
$21.98
Volume
88,547 shs
Average Volume
200,407 shs
Market Capitalization
$402.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.00

Mineralys Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
265.5% Upside
$36.00 Price Target
Short Interest
Bearish
9.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.61mentions of Mineralys Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$2.01 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.49) to ($2.85) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

569th out of 976 stocks

Pharmaceutical Preparations Industry

262nd out of 450 stocks


MLYS stock logo

About Mineralys Therapeutics (NASDAQ:MLYS) Stock

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

MLYS Price History

MLYS Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc (MLYS)
See More Headlines
Receive MLYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mineralys Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MLYS Company Calendar

Last Earnings
8/07/2023
Today
9/28/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MLYS
Fax
N/A
Employees
12
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$36.00
High Stock Price Forecast
$45.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+265.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-29,800,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$402.47 million
Optionable
Not Optionable
Beta
N/A
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Jon Congleton (Age 60)
    CEO & Director
    Comp: $428.87k
  • Mr. Adam Scott Levy (Age 45)
    CFO, Chief Bus. Officer & Sec.
    Comp: $409.17k
  • Dr. David Rodman M.D. (Age 67)
    Chief Medical Officer
    Comp: $423.66k
  • Dr. Brian Taylor Slingsby M.D. (Age 46)
    M.P.H., Ph.D., Founder & Exec. Chairman
  • Ms. Cindy Berejikian
    Exec. VP of Operations
  • Dr. Robert McKean Ph.D.
    Sr. VP of CMC
  • Ms. Danielle Bradbury
    Sr. VP of Quality Assurance
  • Mr. Jeffrey N. Fellows
    Sr. VP of Regulatory Affairs
  • Ms. Jessica Ibbitson
    Sr. VP of Clinical Operations
  • Mr. Jose Breton CPA (Age 33)
    VP of Fin. & Controller













MLYS Stock - Frequently Asked Questions

Should I buy or sell Mineralys Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mineralys Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MLYS shares.
View MLYS analyst ratings
or view top-rated stocks.

What is Mineralys Therapeutics' stock price forecast for 2023?

6 brokerages have issued twelve-month target prices for Mineralys Therapeutics' stock. Their MLYS share price forecasts range from $27.00 to $45.00. On average, they predict the company's share price to reach $36.00 in the next twelve months. This suggests a possible upside of 265.5% from the stock's current price.
View analysts price targets for MLYS
or view top-rated stocks among Wall Street analysts.

How have MLYS shares performed in 2023?

Mineralys Therapeutics' stock was trading at $18.44 at the beginning of the year. Since then, MLYS stock has decreased by 46.6% and is now trading at $9.85.
View the best growth stocks for 2023 here
.

When is Mineralys Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our MLYS earnings forecast
.

How were Mineralys Therapeutics' earnings last quarter?

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) posted its quarterly earnings results on Monday, August, 7th. The company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.83) by $0.52.

When did Mineralys Therapeutics IPO?

(MLYS) raised $180 million in an IPO on Friday, February 10th 2023. The company issued 12,000,000 shares at $14.00-$16.00 per share.

What is Mineralys Therapeutics' stock symbol?

Mineralys Therapeutics trades on the NASDAQ under the ticker symbol "MLYS."

When did Mineralys Therapeutics' lock-up period expire?

Mineralys Therapeutics' lock-up period expired on Wednesday, August 9th. Mineralys Therapeutics had issued 12,000,000 shares in its IPO on February 10th. The total size of the offering was $192,000,000 based on an initial share price of $16.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the expiration of the lock-up period.

Who are Mineralys Therapeutics' major shareholders?

Mineralys Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (2.16%), Sectoral Asset Management Inc. (1.50%), Great Point Partners LLC (1.34%), Driehaus Capital Management LLC (1.22%), Sphera Funds Management LTD. (0.99%) and Geode Capital Management LLC (0.70%). Insiders that own company stock include Adam Scott Levy, David Malcom Rodman, Hbm Healthcare Investments (Ca, Jon Congleton and Ra Capital Management, LP.
View institutional ownership trends
.

How do I buy shares of Mineralys Therapeutics?

Shares of MLYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mineralys Therapeutics' stock price today?

One share of MLYS stock can currently be purchased for approximately $9.85.

How much money does Mineralys Therapeutics make?

Mineralys Therapeutics (NASDAQ:MLYS) has a market capitalization of $402.47 million.

How can I contact Mineralys Therapeutics?

The official website for the company is www.mineralystx.com. The company can be reached via phone at 888-378-6240 or via email at investorrelations@mineralystx.com.

This page (NASDAQ:MLYS) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -